ARTICLE | Clinical News
Viekira Pak ombitasvir/paritaprevir/ritonavir plus dasabuvir regulatory update
December 7, 2015 8:00 AM UTC
FDA accepted an NDA from AbbVie for once-daily Viekira Pak ombitasvir/paritaprevir/ritonavir plus dasabuvir for use with or without ribavirin to treat chronic HCV genotype 1 infection. AbbVie expects ...